Loading clinical trials...
Loading clinical trials...
Evaluation of a POlypill and Colchicine for Risk Reduction in Patients With Established Atherosclerotic Cardiovascular Disease: The EPOCA Randomized Clinical Trial
Conditions
Interventions
Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin)
Colchicine 0.5 mg
+2 more
Locations
13
Brazil
Centro de Pesquisas Clínicas Dr. Marco Mota
Maceió, Alabama, Brazil
Secretária da Saúde do Estado do Ceará - Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Messejana, Ceará, Brazil
Empresa Brasileira de Serviços Hospitalares - EBSERCH - Hospital de Ensino Dr. Washington Antônio de Barros- HU-UNIVASF
Petrolina, Pernambuco, Brazil
Centro de Pesquisa Cardiolima
Teresina, Piauí, Brazil
Fundação Técnico Educacional Souza Marques
Rio de Janeiro, Rio de Janeiro, Brazil
Fundação Universitária de Cardiologia - ICFUC
Porto Alegre, Rio Grande do Sul, Brazil
Start Date
June 12, 2025
Primary Completion Date
May 1, 2031
Completion Date
May 1, 2031
Last Updated
January 22, 2026
NCT06813911
NCT06292013
NCT07311330
NCT05834673
Lead Sponsor
Hospital do Coracao
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions